OTCMKTS:SEOVF Sernova (SEOVF) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free SEOVF Stock Alerts $0.28 -0.02 (-6.67%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.28▼$0.2850-Day Range$0.28▼$0.4752-Week Range$0.28▼$0.83Volume2,538 shsAverage Volume18,991 shsMarket Capitalization$84.95 millionP/E RatioN/ADividend YieldN/APrice Target$1.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Sernova alerts: Email Address Sernova MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside435.7% Upside$1.50 Price TargetShort InterestHealthy0.00% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.24 out of 5 stars 3.0 Analyst's Opinion Consensus RatingSernova has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSernova has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.00% of the outstanding shares of Sernova have been sold short.Short Interest Ratio / Days to CoverSernova has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sernova has recently decreased by 98.22%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSernova does not currently pay a dividend.Dividend GrowthSernova does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SEOVF. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Sernova this week, compared to 0 articles on an average week. Previous Next N/A Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sernova insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Sernova is -3.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sernova is -3.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSernova has a P/B Ratio of 9.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About Sernova Stock (OTCMKTS:SEOVF)Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.Read More SEOVF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SEOVF Stock News HeadlinesMay 1, 2024 | finance.yahoo.comSernova Announces AGM Voting ResultsMarch 11, 2024 | marketwatch.comSernova Names Nicholas Rossettos Interim CFOMay 5, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...January 29, 2024 | msn.comSernova reports anticipated 2024 milestonesNovember 27, 2023 | msn.comSernova gets FDA orphan drug, rare pediatric designations for hemophilia ANovember 14, 2023 | theglobeandmail.comClosing Bell: Sernova Corp flat on Tuesday (SVA)October 30, 2023 | finance.yahoo.comSernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint CongressSeptember 29, 2023 | finance.yahoo.comSernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual MeetingMay 5, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...September 7, 2023 | finance.yahoo.comSernova Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch DeviceSeptember 5, 2023 | marketwatch.comSernova Appoints Cynthia Pussinen as Chief ExecutiveSeptember 5, 2023 | seekingalpha.comSernova appoints CEOJune 26, 2023 | markets.businessinsider.comSernova (SVA) Receives a Buy from H.C. WainwrightJune 22, 2023 | finance.yahoo.comSernova to Present Updated Interim Phase 1/2 Clinical Data on Cell Pouch System™ During Oral Presentation at American Diabetes Association 83rd Scientific SessionsJune 16, 2023 | finance.yahoo.comSernova to Participate in Upcoming Truist Securities Cell Therapy SymposiumJune 15, 2023 | markets.businessinsider.comEchelon Wealth Partners Remains a Buy on Sernova (SVA)May 31, 2023 | finance.yahoo.comSernova Announces Executive Alignment and Appoints New Board ChairMay 8, 2023 | theglobeandmail.comClosing Bell: Sernova Corp flat on Monday (SVA)April 28, 2023 | theglobeandmail.comClosing Bell: Sernova Corp flat on Thursday (SVA)April 25, 2023 | finance.yahoo.comConcerned Shareholders of Sernova Corp. Wish to Thank All ShareholdersApril 10, 2023 | finance.yahoo.comSernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the MedApril 6, 2023 | finanznachrichten.deSernova Corp.: Sernova Responds to Dissident Shareholders' Misleading Statements and Provides Corporate UpdatesMarch 23, 2023 | finance.yahoo.comAdvance Notice Filed with Sernova Corp. for the Nomination of Two Director NomineesMarch 22, 2023 | finance.yahoo.comSernova Announces Abstract on First Cohort of its Phase 1/2 Study Involving Islet Allotransplantation into Pre-vascularized Cell Pouch™ Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions 2023March 2, 2023 | finance.yahoo.comSernova to Participate in Upcoming Roth and Oppenheimer Investor ConferencesJanuary 30, 2023 | marketwatch.comSernova Shares Climb After Study Update on System to Preserve Thyroid FunctionJanuary 30, 2023 | uk.news.yahoo.comSernova Announces Advancements with its Novel Cell Pouch System(TM) to Preserve Thyroid Function Following Total ThyroidectomySee More Headlines Receive SEOVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sernova and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today5/05/2024Next Earnings (Estimated)6/12/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:SEOVF CUSIPN/A CIK1491434 Webwww.sernova.com Phone(519) 858-5184Fax519-858-5184EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$1.50 High Stock Price Target$1.50 Low Stock Price Target$1.50 Potential Upside/Downside+435.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,910,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-226.64% Return on Assets-145.26% Debt Debt-to-Equity Ratio0.14 Current Ratio1.20 Quick Ratio1.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book9.33Miscellaneous Outstanding Shares303,410,000Free FloatN/AMarket Cap$84.95 million OptionableNot Optionable Beta1.20 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMs. Cynthia PussinenCEO & DirectorDr. Philip M. Toleikis B.A.M.Sc., Ph.D., President, CTO, Director of Technology & DirectorDr. Modestus Obochi M.B.A.Ph.D., Chief Business OfficerDr. Frank Shannon M.D.Vice President of Clinical Development & Regulatory AffairsMr. Nicholas J. Rossettos CPA (Age 58)M.B.A., Interim Chief Financial Officer Mr. Douglas MaretChief Science OfficerMr. Christopher BarnesVice President of Investor RelationsMore ExecutivesKey CompetitorsBioXcel TherapeuticsNASDAQ:BTAIOramed PharmaceuticalsNASDAQ:ORMPAllakosNASDAQ:ALLKClearside BiomedicalNASDAQ:CLSDPMV PharmaceuticalsNASDAQ:PMVPView All Competitors SEOVF Stock Analysis - Frequently Asked Questions Should I buy or sell Sernova stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sernova in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SEOVF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SEOVF, but not buy additional shares or sell existing shares. View SEOVF analyst ratings or view top-rated stocks. What is Sernova's stock price target for 2024? 1 equities research analysts have issued 1-year price objectives for Sernova's shares. Their SEOVF share price targets range from $1.50 to $1.50. On average, they expect the company's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 435.7% from the stock's current price. View analysts price targets for SEOVF or view top-rated stocks among Wall Street analysts. How have SEOVF shares performed in 2024? Sernova's stock was trading at $0.5328 at the beginning of 2024. Since then, SEOVF shares have decreased by 47.4% and is now trading at $0.28. View the best growth stocks for 2024 here. Are investors shorting Sernova? Sernova saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 1,900 shares, a drop of 98.2% from the March 31st total of 106,700 shares. Based on an average trading volume of 41,900 shares, the days-to-cover ratio is presently 0.0 days. View Sernova's Short Interest. When is Sernova's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024. View our SEOVF earnings forecast. How were Sernova's earnings last quarter? Sernova Corp. (OTCMKTS:SEOVF) issued its quarterly earnings data on Monday, March, 18th. The company reported ($0.02) earnings per share for the quarter. How do I buy shares of Sernova? Shares of SEOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SEOVF) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sernova Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.